Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT05740813

HEALEY ALS Platform Trial - Regimen F ABBV-CLS-7262

Sponsor: Calico Life Sciences LLC

Conditions Amyotrophic Lateral Sclerosis

Interventions ABBV-CLS-7262 Dose 1 ABBV-CLS-7262 Dose 2 Matching Placebo

Updated 7 times since 2023 Last updated: Oct 31, 2025 Started: Mar 23, 2023 Primary completion: Oct 3, 2024 Completion: Oct 3, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Amyotrophic Lateral Sclerosis, this trial is completed. The trial is conducted by Calico Life Sciences LLC and has accumulated 7 data snapshots since 2023. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Dec 2025 — Present [monthly]

Completed PHASE2/PHASE3
Mar 2025 — Dec 2025 [monthly]

Completed PHASE2/PHASE3

Status: Enrolling By Invitation → Completed
Sep 2024 — Mar 2025 [monthly]

Enrolling By Invitation PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Enrolling By Invitation PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Nov 2023 — Jul 2024 [monthly]

Enrolling By Invitation PHASE2_PHASE3

▶ Show 2 earlier versions

May 2023 — Nov 2023 [monthly]

Enrolling By Invitation PHASE2_PHASE3

Status: Not Yet Recruiting → Enrolling By Invitation
Mar 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Calico Life Sciences LLC
Merit E. Cudkowicz, MD

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States